NCT03073785 - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage I Pancreatic Cancer AJCC v6 and v7Stage IA Pancreatic Cancer AJCC v6 and v7Stage IB Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7Stage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG

Capecitabine

Given by mouth (PO)

DRUG

Fluorouracil

Given Intravenously (IV)

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo hypofractionated stereotactic radiotherapy

DRUG

Zoledronic Acid

Given IV

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER